NHS England has proposed a phased rollout of tirzepatide, a promising weight-loss drug, to benefit patients most likely to ...

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...

The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...

Dallas, Texas, Oct. 03, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 ...

Semaglutide and tirzepatide treatment lead to significant weight loss and improve blood sugar control in individuals with type 1 diabetes (T1D) who are living with overweight or obesity, new research ...

NHS England has asked NICE to consider a slow phased rollout of tirzepatide for weight loss in primary care to avoid overwhelming GPs.

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...

NHS leaders are considering a phased rollout of the obesity injection tirzepatide (Mounjaro, Eli Lilly) because of potentially high demand. The National Institute for Health and Care Excellence (NICE) ...